BioSpace News Archive

Owens & Minor, Inc. announced the early results of its previously announced offers to purchase for cash up to a maximum aggregate purchase price, excluding accrued interest, equal to $240 million of the Company’s 3.875% senior notes due 2021 and 4.375% senior notes due 2024 and related Consent Solicitation, upon the terms and conditions described in the Company’s Offer to Purchase and Consent Solicitation Statement dated June 5, 2020.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020. Certain tasks have been hampered by the Covid pandemic restrictions, similar to other companies in the sector. T

Plakous Therapeutics, Inc. has been granted orphan drug and rare pediatric disease designations for its human placental extract, Protego-PD™, for the prevention of necrotizing enterocolitis (NEC) in early preterm infants.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category for the third year in a row.

Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19.

- More than 15,000 new cases of follicular lymphoma are diagnosed each year in the US, and about 20 percent of patients will relapse within two years, with few treatment options[1] - The new cobas test is a companion diagnostic that detects mutations in the EZH2 gene in follicular lymphoma patients who may be eligible for targeted treatment - Test results can be available in less than a day, aiding clinicians in making timely decisions for effective treatment options that hav

Orthopedics This Week is excited to announce the worldwide launch of the next generation 3D Virtual Convention platform for the Medical Industry: OTW Virtual Conventions.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI™

AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share.

IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced that, in order to replace its prior base shelf prospectus and corresponding shelf registration statement that will expire on July 5, 2020,